Skip to main content

Table 3 Rates of cancers, infection (overall and serious infections), and cardiovascular adverse events

From: Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

  Adverse event rates, events/100 PY   
  Tocilizumab Abatacept Ratio (95% CI) of rates
tocilizumab/abatacept
p value
Cancera 0.61 events/155.2 PY 1.22 events/157.2 PY 0.5 (0.1, 9.7) 0.63
Infection
 All events 54.373 events/135.4 PY 57.179 events/138.3 PY 0.9 (0.7, 1.3) 0.72
 Serious infections 1.93 events/155.2 PY 2.54 events/157.7 PY 0.7 (0.1, 4.5) 0.74
 Cardiovascular 2.54 events/154.6 PY 1.93 events/156.7 PY 1.3 (0.2, 9.2) 0.71
  1. aExcluding nonmelanoma skin cancer
  2. CI confidence interval, PY person-years